+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs



Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs



Journal of Pediatric and Adolescent Gynecology 23(5): 312-316



The importance of diagnosing trichomoniasis is highlighted by its strong association with HIV acquisition and viral shedding. The low sensitivity of wet preparation and often asymptomatic nature of trichomoniasis results in failure to recognize and treat this sexually transmitted infection. The purpose of this study was to evaluate the feasibility of screening high-risk adolescent females using a new highly sensitive and specific NAAT assay. We enrolled a consecutive, clinical sample of 144 sexually active females, aged 13 through 21. Subjects completed a questionnaire on sexual history and current vaginal symptoms, and provided two self- or physician-collected vaginal swabs and urine. A wet preparation test was performed with one swab and the APTIMA Trichomonas vaginalis (ATV) assay (Gen-Probe, Inc.) was performed with the other and with urine. Mean age was 18 +/- 1.6 years; 55% Hispanic and 35% black. A three-fold higher prevalence of trichomoniasis (6.3%) was detected by ATV than by wet preparation (2.1%) with 100% concordance between vaginal swab and urine. Prevalence of chlamydia by APTIMA was 11%; no gonorrhea was detected. Subjects with trichomoniasis were more likely than those without to be black (P < 0.01), and to report past gonorrhea (P < 0.01) and past PID (P < 0.001). No vaginal symptom distinguished those with trichomoniasis. Three times as many cases of trichomoniasis were identified with ATV compared to wet preparation and identical results were obtained with vaginal swabs and urine. No symptoms were associated with trichomoniasis. These findings highlight the imperative and feasibility of screening and treating at-risk populations.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670863

Download citation: RISBibTeXText

PMID: 20493735

DOI: 10.1016/j.jpag.2010.03.004


Related references

Screening for Trichomonas vaginalis in a large high-risk population; Prevalence among Males and Females Determined by Nucleic Acid Amplification Testing. Sexually Transmitted Diseases: -, 2018

Detecting asymptomatic Trichomonas vaginalis in females using the BD ProbeTec™ Trichomonas vaginalis Qx nucleic acid amplification test. International Journal of Std & Aids 28(4): 357-361, 2016

Screening of male patients for Trichomonas vaginalis with transcription-mediated amplification in a community with a high prevalence of sexually transmitted infection. Journal of Clinical Microbiology 51(1): 101-104, 2013

APTIMA® Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens. Expert Review of Molecular Diagnostics 11(7): 679-688, 2012

Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. Journal of Clinical Microbiology 50(8): 2601-2608, 2012

Optimal timing for Trichomonas vaginalis test of cure using nucleic acid amplification testing. Sexually Transmitted Diseases 2019, 2019

Are isolated anti-HBc blood donors in high risk group? The detection of HBV DNA in isolated anti-HBc cases with nucleic acid amplification test (NAT) based on transcription-mediated amplification (TMA) and HBV discrimination. Transfusion and Apheresis Science 43(3): 265-268, 2011

Assessment of screening practices in a subacute clinical setting following introduction of Trichomonas vaginalis nucleic acid amplification testing. Wmj 111(5): 233-236, 2013

A service evaluation of the Gen-Probe APTIMA nucleic acid amplification test for Trichomonas vaginalis: should it change whom we screen for infection?. Sexually Transmitted Infections 91(2): 81-86, 2015

Retrospective assessment of transcription-mediated amplification-based screening for Trichomonas vaginalis in male sexually transmitted infection clinic patients. Journal of Clinical Microbiology 51(6): 1855-1860, 2013

Comparison between the Gen-Probe transcription-mediated amplification Trichomonas vaginalis research assay and real-time PCR for Trichomonas vaginalis detection using a Roche LightCycler instrument with female self-obtained vaginal swab samples and male urine samples. Journal of Clinical Microbiology 44(11): 4197-4199, 2006

Female epidemiology of transcription-mediated amplification-based Trichomonas vaginalis detection in a metropolitan setting with a high prevalence of sexually transmitted infection. Journal of Clinical Microbiology 50(12): 3927-3931, 2013

Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. Journal of Clinical Microbiology 49(3): 866-869, 2011

Impact of Trichomonas vaginalis transcription-mediated amplification-based analyte-specific-reagent testing in a metropolitan setting of high sexually transmitted disease prevalence. Journal of Clinical Microbiology 46(10): 3368-3374, 2008

Trichomonas vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic. Sexually Transmitted Diseases 43(8): 483-488, 2017